Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Routine BRCA testing for ovarian cancer patients proves feasible in irish study

NCT ID NCT06274541

Knowledge-focused Sponsor: Cancer Trials Ireland Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether it is practical to routinely check ovarian cancer tumors for BRCA gene mutations in the clinic. Researchers enrolled 200 patients with high-grade serous or endometrioid ovarian, fallopian tube, or primary peritoneal cancer. They used blood and tumor samples to look for BRCA1/2 mutations, aiming to see if this approach works well for doctors and patients, and if it is cost-effective for the healthcare system.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
BRCA1/2 genetic testing
What this could lead to
If successful, this could make BRCA testing a standard part of ovarian cancer care, helping doctors choose better treatments and informing family members about their cancer risk.
What could go wrong
This was a small pilot study focused on feasibility, not on patient outcomes. The results may not apply to other healthcare systems or populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

200 people

The number who actually took part.

Started

Mar 2019

Finished

Mar 2026

Lead sponsor

A research network

The lead sponsor is a research network or cooperative group.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

All patients with high grade serous or endometrioid ovarian, fallopian tube or primary peritoneal cancer (HGSEC), either at primary diagnosis or first relapse.

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Patients with high grade serous or high grade endometrioid ovarian, fallopian tube or primary peritoneal carcinoma who: Are newly diagnosed FIGO stage I - IV or Are currently undergoing primary chemotherapy +/- surgery or Are in remission after completing primary treatment for FIGO stage I - IV disease or Are being planned for, are undergoing or have completed treatment for first relapse 2. Patients with available tumour tissue (archival FFPE surgical resection or tissue/peritoneal biopsy) obtained prior to chemotherapy delivery, for tumour BRCA1/2 testing 3. Patients able to give signed and written informed consent 4. Patients aged 18 years and above Exclusion Criteria: 1. Patients with non-high grade serous or non-high grade endometrioid ovarian, fallopian tube or primary peritoneal carcinoma or unclear histology 2. Patients in second or later relapse of their disease 3. Patients who are known BRCA1 or BRCA2 mutation carriers 4. Patients who have been previously tested for germline BRCA1/2 mutations or have been tested with a hereditary cancer gene panel.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Endometrioid carcinoma ovary are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

fallopian tube cancer fallopian tube endometrioid adenocarcinoma fallopian tube neoplasm fallopian tube serous adenocarcinoma ovarian endometrioid adenocarcinoma ovarian serous adenocarcinoma ovarian serous tumor primary peritoneal carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Endometrioid carcinoma ovary Fallopian tube cancer Primary peritoneal carcinoma Serous ovarian tumor

Contacts and locations

Locations

  • Bon Secours

    Cork, Munster, Ireland

  • Cork University Hospital

    Cork, Munster, Ireland

  • Mater Misericordiae University Hospital / Mater Private Hospital

    Dublin, Leinster, Ireland

  • St James's Hospital

    Dublin, Leinster, Ireland

  • University Hospital Limerick

    Limerick, Munster, Ireland

More trials for these conditions

Other studies related to the condition(s) this trial covers.